Telix Pharmaceuticals (NASDAQ:TLX) Given Buy Rating at HC Wainwright

Key Points

• HC Wainwright reaffirmed a Buy rating on Telix Pharmaceuticals and set a $20 price target, implying 76.29% upside from the prior close.
• Analyst sentiment remains positive, with MarketBeat reporting a consensus Buy rating and an average target price of $20.50; Wedbush also maintained an Outperform rating with a $22 target.
• Telix shares traded at $11.35, near the 50-day moving average of $11.33, while several institutional investors—including XY Capital, Bank of America and Private Advisor Group—recently increased their positions.

Telix Pharmaceuticals (NASDAQ:TLX - Get Free Report)'s stock had its "buy" rating reaffirmed by HC Wainwright in a research note issued on Friday, Benzinga reports. They currently have a $20.00 price objective on the stock. HC Wainwright's price target would indicate a potential upside of 76.29% from the company's previous close.

TLX has been the topic of several other research reports. Wedbush reiterated an "outperform" rating and issued a $22.00 target price on shares of Telix Pharmaceuticals in a report on Wednesday. Royal Bank Of Canada upgraded shares of Telix Pharmaceuticals from a "hold" rating to a "moderate buy" rating in a report on Monday. Weiss Ratings upgraded shares of Telix Pharmaceuticals from a "sell (d)" rating to a "hold (c-)" rating in a report on Friday, August 21st. Finally, Citigroup reiterated a "buy" rating on shares of Telix Pharmaceuticals in a report on Thursday, August 20th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, Telix Pharmaceuticals presently has a consensus rating of "Buy" and an average target price of $20.50.

Telix Pharmaceuticals Stock Performance

TLX traded up $0.04 during trading on Friday, hitting $11.35. The stock had a trading volume of 223,103 shares, compared to its average volume of 220,852. Telix Pharmaceuticals has a 12 month low of $6.28 and a 12 month high of $13.11. The company has a debt-to-equity ratio of 1.16, a quick ratio of 1.85 and a current ratio of 2.01. The company has a 50 day simple moving average of $11.33 and a 200-day simple moving average of $10.47.

Institutional Trading of Telix Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. XY Capital Ltd grew its position in Telix Pharmaceuticals by 468.0% in the 2nd quarter. XY Capital Ltd now owns 71,291 shares of the company's stock worth $822,000 after purchasing an additional 58,739 shares during the last quarter. Hennion & Walsh Asset Management Inc. acquired a new stake in Telix Pharmaceuticals in the 2nd quarter worth $1,731,000. Bank of America Corp DE grew its position in Telix Pharmaceuticals by 523.8% in the 1st quarter. Bank of America Corp DE now owns 10,031 shares of the company's stock worth $96,000 after purchasing an additional 8,423 shares during the last quarter. Lazard Asset Management LLC grew its position in Telix Pharmaceuticals by 15.7% in the 1st quarter. Lazard Asset Management LLC now owns 289,917 shares of the company's stock worth $2,775,000 after purchasing an additional 39,400 shares during the last quarter. Finally, Private Advisor Group LLC grew its position in Telix Pharmaceuticals by 276.3% in the 1st quarter. Private Advisor Group LLC now owns 174,415 shares of the company's stock worth $1,669,000 after purchasing an additional 128,070 shares during the last quarter.

About Telix Pharmaceuticals

Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing radiopharmaceuticals for the diagnosis and treatment of cancer and other serious diseases. Its products use targeted molecules to deliver radioactive isotopes to specific tissues, supporting precision imaging and therapeutic applications.

The company's commercial portfolio includes Illuccix, a gallium-68 radiolabeled prostate-specific membrane antigen (PSMA) imaging agent used with PET scans to help detect and manage prostate cancer.